Jump to content

Definition:Medical stop-loss

From Insurer Brain

🛡️ Medical stop-loss is a form of reinsurance-like protection purchased by employers who self-fund their employee health benefit plans, designed to cap the financial exposure that arises when claims exceed expected levels. Unlike fully insured group health plans where the carrier assumes all claims risk, self-funded employers bear the cost of employee medical claims directly — and medical stop-loss acts as the safety net that prevents catastrophic losses from destabilizing the employer's finances. The product is typically underwritten by specialized stop-loss carriers or divisions within larger insurers and comes in two forms: specific (individual) and aggregate.

💰 Specific stop-loss triggers when a single covered individual's claims exceed a predetermined attachment point — for instance, $250,000 in a plan year — at which point the stop-loss carrier reimburses the employer for claims above that threshold. Aggregate stop-loss, by contrast, activates when the employer's total plan claims surpass a corridor, usually expressed as a percentage above the expected annual claims liability. Employers work with third-party administrators and benefits consultants to structure these layers, balancing the premium cost of lower attachment points against the risk tolerance of higher self-insured retentions. Actuarial analysis of the employer's historical claims data, demographic profile, and plan design drives the pricing and terms.

📈 The medical stop-loss market has grown substantially as more mid-size and even smaller employers move toward self-funding to gain greater control over health plan costs and claims data. This trend has attracted insurtech entrants that use predictive analytics and real-time claims monitoring to offer more dynamic stop-loss products. For carriers and MGUs operating in this space, disciplined underwriting is essential — a single plan with an unexpectedly high number of catastrophic claims, such as organ transplants or specialty drug therapies, can produce significant loss ratio volatility.

Related concepts: